Patent ID: 11932898
Assignee: UNIVERSITY OF MIAMI
Field: Measurement (Instruments)
Classification: CPC C  G | IPC C  G

Claim 10:
11. A method of grouping drugs for treating a pathology, the method comprising:
receiving, at a processing unit, drug responsiveness data for a set of drugs and for a set of cell lines;
grouping, using the processing unit, each of the drugs into a different drug grouping, using
(i) a generalized finite mixture of multivariate regression (FMMR) model as follows, f
   ⁡
   (
   
    
     
      y
      i
     
     ❘
     
      x
      i
     
    
    ,
    Θ
   
   )
  
  =
  
   
    ∑
    
     
      (
      
       
        l
        1
       
       ⁢
       …
       ⁢
       
        l
        s
       
      
      )
     
     ∈
     T
    
   
   
    
     π
     
      (
      
       
        l
        1
       
       ⁢
       …
       ⁢
       
        l
        s
       
      
      )
     
    
    ⁢
    
     
      f
      ⁡
      (
      
       
        
         y
         i
        
        ❘
        
         x
         i
        
       
       ,
       
        B
        
         l
         1
        
       
       ,
       …
         
       ,
       
        B
        
         l
         s
        
       
       ,
       Σ
      
      )
     
     .
    
   
  
 

 wherein f(yi|xi, Bl1, . . . , Bls, Σ) is a multivarite normal density function generalized for both non-overlapping clusters and overlapping clusters, yi are drug responsiveness values, xi are genomic biomarkers, Bl1, . . . , Bls are coefficient matrix values for a cluster, are clusters, π is an observation value indicating whether a drug belongs in a grouping (π=1) or not (π=0), and Σ is an error term for the coefficient matrix values, i represents a drug,
 wherein the generalized FMMR model allows for modeling drugs for both non-overlapping clusters and overlapping clusters, and
(ii) a clustering algorithm configured to group drugs based on the coefficient matrix values, B, for different drugs and based on cell line assignments to generate a group of alternative drugs corresponding to an overlap cell line cluster having a drug responsiveness value that is between a high drug responsiveness value and a low drug responsiveness value; and
administering one or more of the alternative drugs from one of the drug groupings to a cell line expressing the pathology.